¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѳ»ºÐºñÇÐȸ SICEM 2022(The 10th Seoul International Congress of Endocrinology and Metabolism) (1ÀÏÂ÷) : 2022-10-28

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѳ»ºÐºñÇÐȸ SICEM 2022(The 10th Seoul International Congress of Endocrinology and Metabolism) (1ÀÏÂ÷) : 2022-10-28
±³À°ÀÏÀÚ : 2022-10-28
±³À°Àå¼Ò : ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) SICEM 2022(The 10th Seoul International Congress of Endocrinology and Metabolism) (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : ¹Ú¼¼Çö
¿¬¶ôó : 02-2038-0072  
À̸ÞÀÏ : endo@endocrinology.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 26 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-28 Room 1 08:30~09:20 Pre-Prediabetes: Time To Treat  Ralph A. DEFRONZO(UT Health San Antonio) 
È޽Ġ10-28  09:20~09:30 È޽Ġ () 
±³À°½Ã°£ 10-28 Room 1 09:30~09:50 NAFLD and Cardiometabolic Diseases   Marja-Riitta TASKINEN(University of Helsinki, Finland) 
±³À°½Ã°£ 10-28 Room 1 09:50~10:10 New Insight of Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)  ÀÓ¼ö(¼­¿ïÀÇ´ë ºÐ´ç¼­¿ï´ëº´¿ø ³»ºÐºñ´ë»ç³»°ú) 
±³À°½Ã°£ 10-28 Room 1 10:10~10:30 Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease  Ming-Hua ZHENG(Wenzhou Medical University, China) 
Åä·Ð 10-28 Room 1 10:30~11:00 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 2 09:30~09:50 Key Players of Bone Metabolism  ¹Ú¼®ÀÎ(°í·ÁÀÇ´ë »ýÈ­ÇкÐÀÚ»ý¹°Çб³½Ç) 
±³À°½Ã°£ 10-28 Room 2 09:50~10:10 Osteoclasts Recycle via Osteomorphs during RANKL-stimulated Bone Resorption  Michelle M. MCDONALD(Garvan Institute of Medical Research) 
±³À°½Ã°£ 10-28 Room 2 10:10~10:30 Bone Cell Plays in Energy Metabolism  Megan M. WEIVODA(Division of Hematology, Mayo Clinic, USA) 
Åä·Ð 10-28 Room 2 10:30~11:00 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 3 09:30~09:50 PFAS and Intersections with the Endocrine System  Michele LA MERRILL(University of California, Davis) 
±³À°½Ã°£ 10-28 Room 3 09:50~10:10 PFAS and Thyroid Function  ±è¹ÎÁÖ(¼­¿ïÀÇ´ë ¼­¿ï´ëÇб³º´¿ø °­³²¼¾ÅÍ) 
±³À°½Ã°£ 10-28 Room 3 10:10~10:30 PFAS and Metabolism  Bruce BLUMBERG(University of California, Irvine) 
Åä·Ð 10-28 Room 3 10:30~11:00 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 4 09:30~09:50 The Latest Guideline Update for Complication Management  ±è´ëÁß(¾ÆÁÖÀÇ´ë ¾ÆÁÖ´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú) 
±³À°½Ã°£ 10-28 Room 4 09:50~10:10 How to Find the Optimal Combination for Initial T2DM Treatment?  °­½Å¾Ö(¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 10-28 Room 4 10:10~10:30 What is the Benefit of SGLT2+DPP4I Combination?  ÀÌÁöÀº(À»ÁöÀÇ´ë ÀÇÁ¤ºÎÀ»Áö´ëº´¿ø ³»ºÐºñ³»°ú) 
Åä·Ð 10-28 Room 4 10:30~11:00 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 5 09:30~09:50 Recent Updates on the Management of Thyroid Nodules  ±è¹ÌÁø(ºÎ»êÀÇ´ë ºÎ»ê´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú) 
±³À°½Ã°£ 10-28 Room 5 09:50~10:10 Recent Updates on the Management of Graves¡¯ Disease  ÀÓµ¿ÁØ(°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 10-28 Room 5 10:10~10:30 Recent Updates on the Management of Subclinical Hypothyroidism  ±èÁøÈ­(Á¶¼±ÀÇ´ë Á¶¼±´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú) 
Åä·Ð 10-28 Room 5 10:30~11:00 Åä·Ð  () 
È޽Ġ10-28  11:00~11:10 È޽Ġ () 
±³À°½Ã°£ 10-28 Room 1 11:30~12:10 SF-1 Targets in the Hypothalamus: A Molecular Link Between Energy Balance and Exercise  Joel ELMQUIST(University of Texas) 
±³À°½Ã°£ 10-28 Room 1 12:10~12:30 Key Updates on the Recent Guidelines - PCSK9 Inhibitors for Whom and When? (Endocrinology perspective)  È«ÁØÈ­(À»ÁöÀÇ´ë ´ëÀüÀ»Áö´ëº´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 10-28 Room 1 12:30~12:50 How to Integrate Semaglutide into Clinical Practice - Focusing on case sharing in UK  Adie VILJOEN(East and North Hertfordshire NHS Trust, UK) 
±³À°½Ã°£ 10-28 Room 2 12:10~12:30 How to Find the Optimal Combination Therapy for Patients with Type 2 Diabetes  ÇѽÂÁø(¾ÆÁÖÀÇ´ë ¾ÆÁִ뺴¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 10-28 Room 2 12:30~12:50 How to treat Hypertension in the Metabolic Syndrome  Á¤¼öÁø(ºÎõ¼¼Á¾º´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 10-28 Room 3 12:10~12:30 Evogliptin CVOS: A Nationwide Cohort Study  ¹ÚÁ¤È¯(ÇѾçÀÇ´ë ÇѾç´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú) 
±³À°½Ã°£ 10-28 Room 3 12:30~12:50 Individualized T2DM Treatment: Focused on Recent Treatment Option  ±è»ó¿ë(Á¶¼±ÀÇ´ë Á¶¼±´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú) 
½Ä»ç 10-28  12:50~13:10 ½Ä»ç  () 
±³À°½Ã°£ 10-28 Room 1 14:00~14:40 Adrenal Pathology Update in 2022: What Clinical Endocrinologists Should Know  Hironobu SASANO(Tohoku University) 
È޽Ġ10-28  14:40~14:50 È޽Ġ () 
±³À°½Ã°£ 10-28 Room 1 14:50~15:10 Roles of Denosumab in Cancer Treatment-induced Bone Loss  È«¾Æ¶÷(Chonnam National University) 
±³À°½Ã°£ 10-28 Room 1 15:10~15:30 Overcoming Difficulties of Osteoporosis Management in Patients with Kidney Disease  David KENDLER(University of British Columbia, Canada) 
±³À°½Ã°£ 10-28 Room 1 15:30~15:50 Managing Osteoporosis in Diabetes: Challenges and Strategies with RANKL Inhibitor  Serge FERRARI(University of Geneva) 
Åä·Ð 10-28 Room 1 15:50~16:20 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 2 14:50~15:10 The Genotype-Based Morphology of Aldosterone-producing Adrenocortical Disorders  Hironobu SASANO(Tohoku University) 
±³À°½Ã°£ 10-28 Room 2 15:10~15:30 Chemogenetic Activation of Adrenal Gq Signaling using DREADD technology Causes Hyperaldosteronism, Hypertension and Disrupts Functional Adrenal Zonation  William RAINEY(University of Michigan) 
±³À°½Ã°£ 10-28 Room 2 15:30~15:50 Primary Aldosteronism: What Do We Need to Monitor after Treatment Initiation?  ±è°æÁø(Korea University) 
Åä·Ð 10-28 Room 2 15:50~16:20 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 3 14:50~15:10 Endocrine Disruptors and Thyroid Dysfunction in Association with Autism Spectrum Disorder  ½ÅÇü¹«(Baylor University) 
±³À°½Ã°£ 10-28 Room 3 15:10~15:30 Iodine Nutrition and Thyroid Function in Korea  ¼ÛÀ±ÁÖ(Food Science and Nutrition, The Catholic University of Korea) 
±³À°½Ã°£ 10-28 Room 3 15:30~15:50 Potassium Iodide Therapy in Graves  Nami SUZUKI(Ito hospital, Japan) 
Åä·Ð 10-28 Room 3 15:50~16:20 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 4 14:50~15:10 Organoid Systems for Stem cells and Diseases  Á¤¿µÅÂ(Department of New Biology, DGIST, Korea) 
±³À°½Ã°£ 10-28 Room 4 15:10~15:30 Fusion of Regionally Specified hPSC-derived Organoids Models  ¹ÚÀÎÇö(Yale University) 
±³À°½Ã°£ 10-28 Room 4 15:30~15:50 Patient-derived Organoids Endometrial Disease  Hugo VANKELECOM(KU Leuven) 
Åä·Ð 10-28 Room 4 15:50~16:20 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 5 14:50~15:10 Recent Advances in NAFLD: A Diabetologist Perspective  Paul Chi Ho LEE(The University of Hong Kong, Hong Kong SAR) 
±³À°½Ã°£ 10-28 Room 5 15:10~15:30 Update on NAFLD as a Metabolic Disease  Christos MANTZOROS(Harvard Medical School, USA) 
±³À°½Ã°£ 10-28 Room 5 15:30~15:45 Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)  ¹Ú¿µÁÖ(Seoul National University, Korea) 
±³À°½Ã°£ 10-28 Room 5 15:45~16:00 Adrenal Diseases a Metabolic Perspective  ±èÁ¤Èñ(Seoul National University, Korea) 
Åä·Ð 10-28 Room 5 16:00~16:20 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 1 16:20~16:50 Thiazolidinediones and SGLT2i: A Rational Combination Based on T2DM Pathophysiology  DeFronzo(UT Health San Antonio) 
±³À°½Ã°£ 10-28 Room 1 16:50~17:20 The Role of Thiazolidinedione in Korean Type 2 Diabetes and Long-term Safety and Efficacy of Lobeglitazone  ±è¼º·¡(The Catholic University of Korea) 
Åä·Ð 10-28 Room 1 17:20~17:50 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 2 16:40~17:00 Iodine Intake and Thyroid Disease during and after Pregnancy in Korean Women  ¾ÈÈ­¿µ(Chung-Ang University) 
±³À°½Ã°£ 10-28 Room 2 17:00~17:20 (Tentative Topic) Management of Thyroid Dysfunction in Pregnancy  Kristien BOELAERT(University of Birmingham) 
Åä·Ð 10-28 Room 2 17:20~17:50 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 3 16:20~16:40 Aging-related White Adipose Tissue Remodeling  Qiong Annabel WANG(Molecular and Cellular Endocrinology, City of Hope, Comprehensive Cancer Center) 
±³À°½Ã°£ 10-28 Room 3 16:40~17:00 HIF1a Signaling Drives Adipose Progenitor Dysfunction and Unhealthy Adipose Tissue Remodeling  Mengle SHAO(Institut Pasteur of Shanghai, Chinese Academy of Sciences) 
±³À°½Ã°£ 10-28 Room 3 17:00~17:20 Impacts of Extracellular Matrix Remodeling in Adipose Tissues in Obesity and Cancer   ¹ÚÁö¿µ(Biological Sciences, School of Life Sciences, UNIST) 
Åä·Ð 10-28 Room 3 17:20~17:50 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 4 16:20~16:40 The Emerging Role of Twincretin in the Management of Obesity  ¼ÕÀå¿ø(The Catholic University of Korea, Korea) 
±³À°½Ã°£ 10-28 Room 4 16:40~17:00 Obesity Treatment in Japan  Koutaro Yokote(Chiba University Graduate School of Medicine, Japan) 
±³À°½Ã°£ 10-28 Room 4 17:00~17:20 Novel Obesity Treatment:  Matthias Blüher(University of Leipzig, Germany) 
Åä·Ð 10-28 Room 4 17:20~17:50 Åä·Ð  () 
±³À°½Ã°£ 10-28 Room 5 16:20~16:40 L-type Amino Acid Transporter 1 and Other Novel Treatment Options for Acromegaly  Toru TATENO(University of Alberta) 
±³À°½Ã°£ 10-28 Room 5 16:40~17:00 Treatment of Acromegaly by Rosiglitazone via Upregulating 15-PGDH in Both Pituitary Adenoma and Liver  Zhaoyun ZHANG(Shanghai Medical College, Fudan University) 
±³À°½Ã°£ 10-28 Room 5 17:00~17:20 Novel Therapeutic Target for Aggressive Cushing  Hidenori FUKUOKA(Kobe University) 
Åä·Ð 10-28 Room 5 17:20~17:50 Åä·Ð  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѳ»ºÐºñÇÐȸ SICEM 2022(The 10th Seoul International Congress of Endocrinology and Metabolism) (1ÀÏÂ÷) : 2022-10-28""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï´ëÇб³º´¿ø International Symposium of Transplantation 2022 : 2022-10-28
´ÙÀ½±Û (¿Â¶óÀÎ) ÀÎÇϴ뺴¿ø Çൿ¹ß´ÞÁõÁø : 2022-10-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 45 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 35 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 36 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 44 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 38 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 29 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 12 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 12 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 26 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 14 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 12 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 32 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 23 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 26 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 22 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷